Rapport Therapeutics, Inc. Investment Income, Interest
Rapport Therapeutics, Inc. (RAPP) reported Investment Income, Interest of $4.19 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-05
- Rapport Therapeutics, Inc. investment income, interest for the quarter ending 2026-06-30 was $4.19M, a 51.63% increase year-over-year.
- Rapport Therapeutics, Inc. investment income, interest for the quarter ending 2026-03-31 was $4.36M, a 43.12% increase year-over-year.
- Rapport Therapeutics, Inc. investment income, interest for the quarter ending 2025-12-31 was $4.75M, a 34.03% increase year-over-year.
- Rapport Therapeutics, Inc. investment income, interest for the quarter ending 2025-09-30 was $3.06M, a 25.40% decline year-over-year.
- Rapport Therapeutics, Inc. investment income, interest for fiscal 2025 was $13.62M, a 12.18% increase from fiscal 2024.
- Rapport Therapeutics, Inc. investment income, interest for fiscal 2024 was $12.14M, a 380.33% increase from fiscal 2023.
- Rapport Therapeutics, Inc. investment income, interest for fiscal 2023 was $2.53M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.19M 10-Q · filed 2026-08-05 | $8.55M 10-Q · filed 2026-08-05 | $13.29M derived: sum of 3 quarters · filed 2026-08-05 | $16.36M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $4.36M 10-Q · filed 2026-05-07 | $9.10M derived: sum of 2 quarters · filed 2026-05-07 | $12.16M derived: sum of 3 quarters · filed 2026-05-07 | $14.93M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $4.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $7.81M derived: sum of 2 quarters · filed 2026-03-10 | $10.57M derived: sum of 3 quarters · filed 2026-08-05 | $13.62M 10-K · filed 2026-03-10 |
| 2025-09-30 | $3.06M 10-Q · filed 2025-11-06 | $5.83M derived: sum of 2 quarters · filed 2026-08-05 | $8.87M 10-Q · filed 2025-11-06 | $12.41M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $2.76M 10-Q · filed 2026-08-05 | $5.81M 10-Q · filed 2026-08-05 | $9.35M derived: sum of 3 quarters · filed 2026-08-05 | $13.45M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $3.04M 10-Q · filed 2026-05-07 | $6.59M derived: sum of 2 quarters · filed 2026-05-07 | $10.69M derived: sum of 3 quarters · filed 2026-05-07 | $13.37M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $3.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $7.64M derived: sum of 2 quarters · filed 2026-03-10 | $10.32M derived: sum of 3 quarters · filed 2026-03-10 | $12.14M 10-K · filed 2026-03-10 |
| 2024-09-30 | $4.10M 10-Q · filed 2025-11-06 | $6.78M derived: sum of 2 quarters · filed 2025-11-06 | $8.60M 10-Q · filed 2025-11-06 | $9.97M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $2.68M 10-Q · filed 2025-08-07 | $4.49M 10-Q · filed 2025-08-07 | $5.87M derived: sum of 3 quarters · filed 2025-08-07 | $6.72M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.81M 10-Q · filed 2025-05-08 | $3.19M derived: sum of 2 quarters · filed 2025-05-08 | $4.05M derived: sum of 3 quarters · filed 2025-05-08 | $4.27M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $2.23M derived: sum of 2 quarters · filed 2025-03-11 | $2.45M derived: sum of 3 quarters · filed 2025-03-11 | $2.53M 10-K · filed 2025-03-11 |
| 2023-09-30 | $856.00K 10-Q · filed 2024-11-07 | $1.08M derived: sum of 2 quarters · filed 2024-11-07 | $1.15M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $221.00K 10-Q · filed 2024-08-08 | $296.00K 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |